Akebia Therapeutics, Inc. has reported its financial results for the third quarter of 2026, revealing significant growth in the number of patients using its product, Vafseo. This update is crucial as it highlights the company's efforts to solidify Vafseo as the standard treatment for anemia in patients undergoing dialysis.

Akebia Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease. The company trades under the ticker symbol AKBA on the Nasdaq exchange. Recent filings include a Form 8-K on November 5, 2026, which details the company’s performance and developments.

The filing states, "On November 5, 2026, Akebia Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026 and recent business highlights." This press release, which is included as Exhibit 99.1, outlines the company's progress and financial metrics.

In the filing, Akebia highlighted that the number of patients on Vafseo increased to approximately 11,500 at the end of Q3 2026, marking a 140% rise compared to the previous year. However, the net product revenues for Vafseo in Q3 2026 were reported at $14.8 million, impacted by customer inventory reductions and market dynamics as the product's Transitional Drug Add-on Payment Adjustment (TDAPA) expiration approaches.

The company also reported positive data from its VOICE trial, indicating statistically significant safety improvements for patients treated with vadadustat compared to those on erythropoiesis-stimulating agents (ESA). Akebia is optimistic about the future, with plans to expand Vafseo's access beyond TDAPA-only patients to nearly all clinically eligible patients by 2027.

The developments reported in this filing may affect various stakeholders, including patients, healthcare providers, and competitors in the pharmaceutical industry. As Akebia continues to enhance its market position, other companies in the pharmaceutical preparations sector may feel compelled to innovate and respond to Akebia's advancements.

Looking ahead, Akebia is expected to continue its efforts to promote Vafseo as the standard of care for anemia in dialysis patients. The filing does not specify what happens next, but the company is likely to host a conference call to discuss these results further.